Core Insights - Intuitive Machines acquired Lanteris Space Systems for $800 million, transitioning from a lunar lander operator to an integrated space platform [1] - The company raised $175 million at a share price of $15.12, resulting in a 360% increase in shares outstanding since 2023 [1] - Despite the acquisition, Intuitive Machines reported a Q3 2025 revenue of $52.4 million and a net loss of $10 million, with an adjusted EBITDA of negative $13.2 million [1] Financial Performance - The stock trades at 11 times trailing revenue, significantly higher than the sector median of 2 times [1] - Total debt stands at $371 million, with accumulated losses of negative $397 million [1] - The latest equity raise led to a 15.93% drop in premarket trading on announcement day [1] Market Sentiment - Reddit sentiment around Intuitive Machines has shifted from a quarterly average of 70.2 (bullish) to a weekly average of 57.7 (neutral) [1] - Discussions on Reddit reflect concerns about the company's revenue projections and dilution trajectory [1] - Analyst ratings show seven out of nine covering analysts rate the stock as a Buy, with a consensus price target of $18.89 [1] Strategic Outlook - The acquisition is seen as a move into multi-billion-dollar space programs, with CEO Steve Altemus emphasizing the potential for significant revenue growth [1] - The upcoming NASA Lunar Terrain Vehicle contract decision is viewed as a critical catalyst for the company's future [1] - The price target range from analysts varies significantly, indicating differing opinions on the credibility of the company's pivot strategy [1]

Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]

Law Offices of Frank R. Cruz Encourages Navan, Inc. (NAVN) Shareholders To Inquire About Securities Fraud Class ActionFeb 26, 2026 12:06 PM Eastern Standard Time# Law Offices of Frank R. Cruz Encourages Navan, Inc. (NAVN) Shareholders To Inquire About Securities Fraud Class ActionShare---LOS ANGELES-- ([BUSINESS WIRE])-- [The Law Offices of Frank R. Cruz] announces that a class action lawsuit has been filed on behalf of shareholders who purchased or otherwise acquired Navan, Inc. ("Navan†or the "Company†) ...

Down 70% over the past year -- and down 60% over just the last three months -- Hims & Hers Health (NYSE: HIMS) stock is in a funk, and Monday night's earnings report didn't help. Shares of the telemedicine company have slid steadily since the FDA announced early last year that Novo Nordisk's (NYSE: NVO) Wegovy and Ozempic GLP-1 weight loss drugs are no longer in shortage. Since that news came out, the writing has seemed to be on the wall for Hims & Hers Health and its business of compounding copycat weigh ...

GRNJ ranks among the fastest-growing actively managed small- and mid-cap equity ETF launches with more than $384 million in AUM1NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Fundstrat Capital, the investment management firm led by Chief Investment Officer Thomas "Tom" Lee, announced the completion of the February 2026 quarterly rebalance for the Fundstrat Granny Shots US Small- & Mid-Cap ETF (NYSE:GRNJ). With more than $384 million in assets under management, as of Feb. 23, 2026, GRNJ ranks among the fastest-grow ...

22% Collapse Looks Like A 'Buy The Dip' Moment[Austin Smith | Feb 9, 2026 at 11:59 AM EST Shares of Hims & Hers Health (NYSE:HIMS) plunged 22% at market open on Monday, February 9. The telehealth company pulled…]## What Losing CNN Means for Snap's Future[Jon C. Ogg | Dec 24, 2017 at 9:59 AM EST Snap has a serious issue about how it can and will grow its user base and engagement. And it has…]## Investor Bets $100k On David v Goliath Matchup With Altimmune and Eli Lilly[Michael Williams | Jan 23, 2026 at 2:06 ...

Group 1: Software Stocks Performance - Major indices were boosted by significant increases in software-related stocks, with Salesforce and ServiceNow both rising by 3% and the iShares Expanded Tech – Software Sector ETF (IGV) gaining 2%, although it remains over 30% lower than its 52-week peak [1] - Retail clients are cautious and waiting for new AI product announcements, interpreting news about Anthropic as competition for legacy applications, which has contributed to a less aggressive market upturn [2] Group 2: Earnings Season Insights - Home Depot exceeded expectations for its fourth quarter, reporting better EPS and revenue, leading to a 2.7% increase in its stock [3] - Keysight Technologies experienced a significant stock surge of 15% after reporting better earnings per share and revenue, while Hims & Hers Health's stock fell nearly 7% due to lower than expected first quarter revenue guidance [4] - Diamondback Energy's stock declined by 3% following the release of lower than expected adjusted earnings [4] Group 3: Economic Concerns - The 10% tariff imposed by the U.S. has raised concerns about its impact on other economies, with speculation that President Trump may increase the tariff to 15%, leading to a risk-averse stance among investors [5]

Chicago Fed President Austan Goolsbee said, "I remain optimistic that there can be more rate cuts this year, but that hinges on seeing actual progress on inflation that shows we are on a path back to 2%."The US Dec S&P composite-20 home price index rose +0.47% m/m and +1.38% y/y, stronger than expectations of +0.30% m/m and +1.30% y/y.Geopolitical risks are a negative for stocks. US-Iran nuclear talks are scheduled to resume on Thursday in Geneva, and Iranian Foreign Minister Araghchi said he saw a “good ch ...

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly.Top 5 Upgrades: Raymond James double upgraded Genuine Parts (GPC) to Strong Buy from Market Perform with a $145 price target. The firm now sees a "constructively asymmetric" setup for the shares based on "conservative sum-of-the-parts math."Seaport Research upgraded Fox Corp. (FOXA) to Buy from Neutral with a $64 price target. Th ...

Core Viewpoint - Hims & Hers Health reported mixed financial results for Q4 2025, with revenue slightly below expectations despite a year-over-year growth of 28% [1] Financial Performance - Q4 2025 revenue reached $617.82 million, which is lower than the expected $619.22 million [1] - Earnings per share (EPS) were $0.08, exceeding the forecast of $0.03 [1] - The company has over 2.5 million subscription users [1] - Gross margin decreased from 77% a year ago to 72% [1] Future Guidance - For Q1, the company expects revenue between $600 million and $625 million, below the anticipated $653.12 million [1] - For the fiscal year 2026, revenue is projected to be between $2.7 billion and $2.9 billion, slightly below the market expectation of $2.74 billion [1]